Evidence‑Based Diagnosis and Management of Vaginitis in Adults

Diagnostic Approach

• Clinical symptoms (pruritus, discharge, odor, burning, dyspareunia) overlap among trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis, so diagnosis cannot rely on symptoms alone. [CDC 1998] [1][2]3
• Vaginal pH ≤ 4.5 favors vulvovaginal candidiasis; pH > 4.5 suggests bacterial vaginosis or trichomoniasis. [CDC 1998] [1][2]3
• Wet‑mount microscopy performed at point‑of‑care can identify yeast/pseudohyphae (candidiasis), clue cells (bacterial vaginosis), or motile trichomonads (trichomoniasis). [CDC 1998] [1][2]
• A 10 % potassium hydroxide (KOH) preparation improves yeast visualization; a positive “whiff” test (amine odor) supports bacterial vaginosis. [CDC 1998] [1][2]3
• Nucleic‑acid amplification tests (NAAT/PCR) have a sensitivity of ≈ 91 % versus ≈ 58 % for clinical diagnosis; they should be used when available. [Clinical Infectious Diseases 2022] 4
• Vaginal culture remains the gold standard for confirming candidiasis when microscopy is negative and for identifying non‑albicans Candida species. [CDC 1998] [1][2]4
• Microscopy detects trichomoniasis with only 60‑70 % sensitivity; culture or NAAT is preferred for accurate diagnosis. [CDC 2002] [5][6]7
• Approximately 50 % of patients receive empiric vaginitis therapy without objective testing, contributing to treatment failure. [Clinical Infectious Diseases 2022] 4
• Between 10‑20 % of asymptomatic women harbor Candida; a positive culture in the absence of symptoms should not trigger treatment. [CDC 1998] [1][2]3

Trichomoniasis Management

• First‑line therapy: metronidazole 2 g orally as a single dose. [CDC 2002] [5][6]7
• Alternative regimen: metronidazole 500 mg orally twice daily for 7 days. [CDC 2002] [5][6]7
• Both regimens achieve cure rates of 90‑95 %. [CDC 1998; CDC 2002] [1][5]6
• Metronidazole vaginal gel is not recommended; efficacy is < 50 % because therapeutic levels are not reached in the urethra and perivaginal glands. [CDC 2002] [5][6]7
• Management of treatment failure:
  
  • First failure – retreat with metronidazole 500 mg twice daily for 7 days. [CDC 2002] [5][6]7
  • Second failure – metronidazole 2 g once daily for 3‑5 days. [CDC 2002] [5][6]7
  • Persistent failure – refer to a specialist for susceptibility testing. [CDC 2002] [5][6]7
• All sexual partners should be treated to prevent reinfection. [CDC 1998; CDC 2002] [1][5]6
• Patients should abstain from sexual activity until both partners have completed therapy and are asymptomatic. [CDC 2002] [5][6]7
• Because trichomoniasis is sexually transmitted, concurrent testing for chlamydia, gonorrhea, and HIV is recommended. [CDC 2015] 8
• Metronidazole 2 g single dose is safe in any trimester of pregnancy. [CDC 2002] [6][7]
• The same regimen is appropriate for HIV‑positive patients. [CDC 2002] [5][6]7

Vulvovaginal Candidiasis (VVC) Management

• Uncomplicated VVC (mild‑to‑moderate, sporadic, Candida albicans in immunocompetent hosts):
  
  • Over‑the‑counter intravaginal options:
    
    • Clotrimazole 1 % cream 5 g daily for 7‑14 days. [CDC 1998] 3
    • Miconazole 2 % cream 5 g daily for 7 days. [CDC 1998] 3
    • Miconazole 200 mg suppository daily for 3 days. [CDC 1998] 3
    • Tioconazole 6.5 % ointment 5 g single application. [CDC 1998] 3
  • Prescription options:
    
    • Fluconazole 150 mg oral single dose (most convenient). [CDC 1998] 2
    • Terconazole 0.4 % cream 5 g daily for 7 days. [CDC 1998] 3
    • Terconazole 80 mg suppository daily for 3 days. [CDC 1998] 3
• All azole regimens achieve cure rates of 80‑90 %. [CDC 1998] [1][2]3
• Topical azoles are more effective than nystatin. [CDC 1998] [1][2]
• Complicated VVC (severe symptoms, recurrent episodes, non‑albicans species, immunocompromise, uncontrolled diabetes, or pregnancy):
  
  • Requires extended topical azole therapy for 7‑14 days. [CDC 1998; Clinical Infectious Diseases 2022] [2][4]
  • Vaginal culture is recommended to identify non‑albicans species. [CDC 1998; Clinical Infectious Diseases 2022] [2][4]
  • Recurrent VVC (≥ 4 episodes/year) – consider prolonged suppressive therapy after initial cure. [Clinical Infectious Diseases 2022] 4
• Pregnancy: only topical azole agents are recommended; oral fluconazole should be avoided. [Clinical Infectious Diseases 2022] 4
• HIV‑positive patients may follow the same treatment regimens as immunocompetent patients. [CDC 1998] [1][2]3
• Partner treatment is not required because VVC is not sexually transmitted. [CDC 1993; CDC 1998] [9][2]

Bacterial Vaginosis (BV) Management

• First‑line therapy: metronidazole 500 mg orally twice daily for 7 days, or intravaginal metronidazole or clindamycin preparations. [CDC 1993; CDC 2002] [10][5]11

Clinical Pitfalls

• Empiric treatment without objective diagnosis is common and often ineffective; molecular testing should be employed when available to improve diagnostic accuracy. [Clinical Infectious Diseases 2022] 4

All statements are based on cited evidence; strength of recommendation was not explicitly graded in the source documents.